Literature DB >> 10340837

A call to action for more aggressive treatment of hypertension.

C Lenfant1, E J Roccella.   

Abstract

During the past three decades, tremendous progress has been made in the USA and many other nations in detecting and controlling hypertension. Health education efforts increased public knowledge of the benefits of treating hypertension, and rates of blood pressure control improved. Despite improvements in the past, however, more recent information has shown some disturbing trends; we are not as healthy a nation as we could be. Hypertension control rates are no longer improving, and are likely to fall short of the US Healthy People 2000 goal of blood pressure control in 50% of all hypertensive patients. Overwhelming data from clinical trials underscore the need to control hypertension, especially in the elderly, for whom hypertension control rates are lower than they are for the total US population. Data from the Framingham Study indicate that the incidence of heart failure increases with age and is greater in hypertensive patients than in normotensive patients. Hypertension precedes heart failure in 90% of all cases, and the prevalence of heart failure, greater today than it was a decade ago, is now the largest component of the Medicare budget (Medicare is the US health insurance and standards for medical participation program for those aged 65 years and older). Hypertension is also associated with an increase in the incidence of end-stage renal disease, and stroke and coronary heart disease may be increasing again. Such alarming trends are a call to action for the public, patients, and health professionals. Strong evidence supports the need for better blood pressure control, with an emphasis on the elderly and other difficult-to-treat populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340837

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  4 in total

Review 1.  Control of cardiomyocyte gene expression as drug target.

Authors:  H Rupp; M Benkel; B Maisch
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 2.  Desirable therapeutic characteristics of an optimal antihypertensive agent.

Authors:  Lisa Mustone Alexander
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension.

Authors:  F Fernández-Vega; J Abellan; S Sanz de Castro; J M Cucalón; B Maceira; A Gómez de la Cámara
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

4.  Controlling high blood pressure: the art of the soluble and the hope of progress.

Authors:  George A Mensah
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.